Month: January 2025

World Businesses for Sale Helps Enterprise Clients Sell their Businesses in an Average of Just Three Months or Less

The team at WorldBusinessesforSale.com offers expert guidance for entrepreneurs, CEOs, and more around the world who are interested in expediting the business sales process

The team at World Businesses for Sale is helping entrepreneurs and business owners take control of their business sales with a track record of closing business sales in an average of three months or less. World Business for Sale has quickly become a trusted resource for those looking to buy and sell businesses.

World Businesses for Sale is an esteemed platform for buying and selling businesses and offers a central hub where business owners across a myriad of categories and scopes are successfully acquiring and selling businesses. Martin Linly, marketing manager at World Businesses for Sale, said, “Selling a business can be a daunting task, but we aim to simplify it. Our focus is on providing the tools and support needed to help business owners sell faster, whether it’s a small local shop or a larger enterprise.”

Selling a business can be a complex and time-consuming process that entails multiple rounds of paperwork, legalities, marketing, vetting, and negotiations. It’s very common for business owners to choose a broker to help with the sale of their business. That’s where World Businesses for Sale shines. The experts at World Businesses for Sale have curated no-commission and low-commission options and a pay-as-you-go plan that can be canceled at any time. Expert listing creation is offered, as well as strategic negotiation support and more to ensure that business owners receive the best deal possible.

Before signing up, however, business owners are invited to visit the World Businesses for Sale website and read success stories and case studies from other satisfied clients who have used the platform to sell and buy businesses. In addition, prospective clients can learn valuable insights regarding business valuation, swift sales, and much more. When they’re ready to move forward, business owners simply connect with World Businesses for Sale to get started.

Learn more now by visiting https://worldbusinessesforsale.com/.

ABOUT WORLD BUSINESSES FOR SALE

World Businesses for Sale offers guidance and resources for pursuing international enterprise opportunities. Follow on social media:

Facebook: @WorldBusinessforSale

YouTube: @WorldBusinessesForSale

Media Contact
Company Name: World Businesses for Sale
Email: Send Email
Phone: +44 (0)121 818 6200
City: Birmingham
Country: United Kingdom
Website: https://worldbusinessesforsale.com/

The UK Data Center Colocation Market Revenue Projected to Reach $8.25 Billion by 2029 – Arizton

“U.K. Data Center Colocation Market Research Report by Arizton”

According to Arizton’s latest research report, the UK data center colocation market is growing at a CAGR of 14.35% during 2023-2029.

                    

Looking for More Information? Click: https://www.arizton.com/market-reports/uk-data-center-colocation-market

    

Report Scope:                    

Market Size – Colocation Revenue (2029): $8.25 Billion                        

CAGR – Colocation Revenue (2023-2029): 14.35%    

Market Size – Utilized White Floor Area (2029): 13.51Million Sq. Ft.   

Market Size – Utilized Racks (2029): 368.41 Thousand Units    

Market Size – Utilized IT Power Capacity (2029): 2,820 MW

Base Year: 2023                            

Forecast Year: 2024-2029         

 

Industrial Hubs and Colocation Growth in the UK

The UK is a significant hub for industrial parks and estates in the Western European region, with key locations including Ransomes Industrial Estate, Slough Trading Estate, Thorp Arch Trading Estate, Springfield Road Industrial Area, and Trafford Park. To meet the increasing demand for colocation services, operators such as Ark Data Centres, Datum, Kao Data, and Pulsant are actively expanding their infrastructure by constructing and upgrading data center facilities. As of March 2023, the cost of industrial land ranged between $3–$7 per square foot, with prices varying by region. Higher costs are observed in West London and North London, while comparatively lower prices are seen in South London and East London.

 

The UK Growing ImportanceRole of UK in the Data Center Market

In the Western European landscape, the UK has emerged as a prominent player in the data center market. Its robust submarine cable infrastructure, which connects key global data center hubs, makes the country an attractive destination for significant investments and operational expansion by leading global cloud operators.

Renowned players in the cloud services sector, including AWS, Microsoft, Google, Alibaba, Tencent, IBM, and Oracle, have firmly established their presence in the thriving UK market.

In November 2023, Google made a strategic move by acquiring a 129-acre plot (formerly Arena Essex Raceway) in Purfleet, Essex, for $57.3 million. This development, located in the PowerGate neighborhood, aligns with the rising demand for data centers in the UK, marking it as a key investment in Google’s infrastructure portfolio.

Similarly, in October 2023, Microsoft committed to expanding its data center presence with plans for a new facility in Newport, Wales. The company confirmed its intention to seek planning permission for a data center at Quinn Imperial Park, reinforcing its ongoing investment in data center infrastructure. The location, near Vantage’s Newport campus, further strengthens the region as a critical hub for tech and data center developments.

The influx of major global cloud service providers, strategic investments by tech giants like Google and Microsoft, and collaborations between governmental departments and leading cloud service firms underscore the UK’s pivotal role in the evolving data infrastructure landscape.

 

Colocation Services Market Revenue and Trends

As of June 2024, revenue generated for colocation services ranges between $1 million to $4 million per megawatt (MW). In 2023, the total revenue from existing colocation operators reached approximately $3.69 billion, with retail colocation operators currently holding the largest market share.

However, market forecasts indicate a shift in dynamics, with revenue from wholesale colocation expected to grow significantly. Wholesale colocation is projected to contribute 50% to 60% of the total market revenue during the forecast period. This growth is largely driven by the expansion of major cloud service providers, including Microsoft, Google, and Amazon Web Services, which are increasingly adopting hyperscale colocation services to meet their infrastructure needs.

Additionally, the entry of new players into the market is expected to drive competition, leading to a decline in the cost of wholesale and hyperscale colocation services.

 

Report Overview

The report includes detailed insights on the following:

 

Colocation Supply

  • Measured in MW (Megawatts), Area, and Rack Capacity.

 

Colocation Demand

  • Breakdown by MW, Area, and Rack Capacity.
  • Further segmentation by End-User Industry, including:
  • Cloud/IT Services
  • BFSI (Banking, Financial Services, and Insurance)
  • And other relevant sectors.

 

Colocation Revenue

  • Analysis of Retail Colocation Services and Wholesale Colocation Services.
  • Competitive Scenario

 

Market Share Analysis by:

  • Revenue
  • MW Capacity

 

Looking for More Information? Click: https://www.arizton.com/market-reports/uk-data-center-colocation-market

 

Vendor Landscape

 

Existing Operators

  • Equinix
  • Virtus Data Centres
  • Ark Data Centres
  • Digital Realty
  • Telehouse
  • Vantage Data Centers
  • Global Switch
  • CyrusOne
  • NTT Global Data Centers
  • Colt Data Centre Services
  • Other Operators

 

Upcoming Colocation Operators

  • Ada Infrastructure
  • CloudHQ
  • Digital Reef
  • EID LLP
  • Global Technical Realty & KKR
  • J Mould
  • Kennedy Wilson
  • Link Park Heathrow
  • Wilton International
  • Humber Tech Park
  • Yondr

 

The Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the UK data center colocation market. Request for Free Sample to get a glance of the report now: https://www.arizton.com/market-reports/uk-data-center-colocation-market

 

What Key Findings Our Research Analysis Reveals?

What is the count of existing and upcoming colocation data center facilities in the United Kingdom?

Who are the new entrants in the United Kingdom’s data center industry?

How much MW of IT power capacity is likely to be utilized in the United Kingdom by 2029?

What factors are driving the U.K. data center colocation market?

   

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4643

 

Other Related Reports that Might be of Your Business Requirement 

United Kingdom Data Center Market – Investment Analysis & Growth Opportunities 2024–2029

https://www.arizton.com/market-reports/uk-data-center-market-investment-analysis

Poland Data Center Colocation Market – Supply & Demand Analysis 2024-2029

https://www.arizton.com/market-reports/poland-data-center-colocation-market

 

Why Arizton?

100% Customer Satisfaction

24×7 availability – we are always there when you need us

200+ Fortune 500 Companies trust Arizton’s report

80% of our reports are exclusive and first in the industry

100% more data and analysis

1500+ reports published till date

 

Post-Purchase Benefit

  • 1hr of free analyst discussion
  • 10% off on customization

 

About Us:

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1 3122332770
Country: United States
Website: https://www.arizton.com/market-reports/uk-data-center-colocation-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The UK Data Center Colocation Market Revenue Projected to Reach $8.25 Billion by 2029 – Arizton

Reshaping Autoimmune Therapy Landscape: Protheragen Announces Small Molecule Drug Development Services for Autoimmune Diseases

Protheragen announced its comprehensive small molecule drug development services aimed at advancing innovative therapies for a range of autoimmune diseases.

New York, USA – Protheragen announced its comprehensive small molecule drug development services aimed at advancing innovative therapies for a range of autoimmune conditions. From target identification to preclinical studies, Protheragen leverages its expertise in small molecule drug design and development to offer tailored services that provide biotech and pharmaceutical companies with the tools necessary to develop small molecule approaches to treat autoimmune diseases.

Autoimmune diseases arise when the immune system mistakenly targets and attacks the body’s own healthy tissues and cells, treating them as if they were harmful invaders. In severe cases, such as with lupus, and rheumatoid arthritis, this can result in chronic inflammation, pain, and damage to various organs or systems. Now, the mechanisms and feasible therapies for these disorders are currently being studied by researchers. Small molecule drug development is one promising area of research, aiming to create targeted therapies that can modulate the immune response more precisely.

As a leading research service provider engaged in autoimmune and inflammatory disease research, Protheragen introduces its specialized small molecule drug development services to accelerate the discovery and development of novel treatments for autoimmune diseases. Equipped with cutting-edge technologies and staffed by a team of experienced scientists, Protheragen can conduct a full spectrum of drug research activities including target identification and validation, drug candidate screening, lead optimization, and preclinical testing. Meanwhile, Protheragen places a strong emphasis on integrating the latest advancements in drug discovery methodologies, including artificial intelligence and machine learning, to enhance their development pipeline and improve time-to-market for new therapies.

Looking ahead, Protheragen aims to expand its portfolio by exploring additional therapeutic areas beyond autoimmune disorders, tapping into the potential of its innovative drug development platform. Through partnerships with academic institutions and industry leaders, the company seeks to accelerate the translation of scientific discoveries into meaningful treatments that can improve the lives of patients suffering from autoimmune and inflammatory diseases.

About Protheragen

Protheragen is dedicated to meeting preclinical research needs in the study of autoimmune diseases. Whether researchers are conducting studies on new or modified medications, medical devices, or therapeutic regimes for autoimmune diseases, Protheragen is here to help. With its skilled technical team and top-notch platform, the company can offer a wide range of autoimmune disease models, solutions for diagnostic development, and professional autoimmune and inflammatory disease research services to expedite effective therapy development for these diseases.

Media Contact
Company Name: Protheragen
Contact Person: Selina Green
Email: Send Email
Phone: 1-631-371-3915
Country: United States
Website: https://www.autoimmunetec.com

Gastrointestinal Stromal Tumor Therapeutics Market Size in the 7MM was ~USD 450 Million in 2023, is expected to grow by 2034, and estimated DelveInsight

DelveInsight’s report titled “Gastrointestinal Stromal Tumor (GIST) Market Insights, Epidemiology, and Market Forecast – 2034” comprehensively analyzes Gastrointestinal Stromal Tumor (GIST). The report provides a comprehensive analysis of historical and projected epidemiological data, covering Total Incident Cases of Gastrointestinal Stromal Tumor (GIST), Gender-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST), Age-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST), Mutation-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST), and Stage-specific Incident Cases of Gastrointestinal Stromal Tumor (GIST).

 

Discover Key Insights into the Gastrointestinal Stromal Tumor Market with DelveInsight’s In-Depth Report @ Gastrointestinal Stromal Tumor Market Size

 

Key Takeaways from Gastrointestinal Stromal Tumor Market Report

  • In the assessment done by DelveInsight, the estimated total incident cases of GIST in the 7MM were nearly 16 thousand in 2023.
  • The highest incident cases of GIST were accounted by the US in 2023 (approximately 7k cases), which are expected to show a steep rise soon due to the improvement in diagnostic testing and advancements in genetic testing and accounts for 43% of the total cases in the 7MM.
  • In 2023, the age-specific incident cases of GIST accounted highest in the age group 66-80 years with nearly 6 thousand cases in the 7MM, followed by age group 51-65 years with around 5 thousand cases. While the least number of cases were seen in the age group 0-17 years.
  • Among the European countries, Germany had the highest incident population of GIST with nearly 2 thousand cases, followed by Italy, which had incident population of over 1k in 2023. On the other hand, Spain had the lowest incident population.
  • Japan had more than 2,500 incident cases for GIST in 2023, accounting for approximately 16% of total incident cases in the 7MM.
  • In 2023, our estimations indicate that within the 7MM, a higher percentage of males (52%) were affected by Gastrointestinal Stromal Tumor (GIST) compared to females (48%). The reason for this gender difference could be attributed to various factors, including potential differences in genetic susceptibility, hormonal influences, occupational exposures, lifestyle habits, and healthcare-seeking behaviors.
  • The leading Gastrointestinal Stromal Tumor Companies such as Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others
  • Promising Gastrointestinal Stromal Tumor Therapies such as TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others

 

Stay ahead in the Gastrointestinal Stromal Tumor Therapeutics Market with DelveInsight’s Strategic Report @ Gastrointestinal Stromal Tumor Market Outlook

 

Gastrointestinal Stromal Tumor Epidemiology Segmentation in the 7MM

  • Total Gastrointestinal Stromal Tumor Prevalence
  • Prevalent Cases of Gastrointestinal Stromal Tumor by severity
  • Gastrointestinal Stromal Tumor Gender-specific Prevalence
  • Diagnosed Cases of Episodic and Chronic Gastrointestinal Stromal Tumor

 

Download the report to understand which factors are driving Gastrointestinal Stromal Tumor epidemiology trends @ Gastrointestinal Stromal Tumor Prevalence

 

Gastrointestinal Stromal Tumor Marketed Therapies

 

  • Ayvakit (Avapritinib): Blueprint Medicines Corporation

Ayvakit is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations and Advanced Systemic Mastocytosis (AdvSM). The FDA granted full approval to Ayvakit based on efficacy results from the Phase I NAVIGATOR clinical trial, as well as combined safety results from multiple clinical trials for avapritinib.

 

  • STIVARGA (Regorafenib): Bayer

Stivarga (BAY 73-4506) is the brand name for the generic chemotherapy agent regorafenib, an oral anticancer medication approved by the FDA for individuals with locally advanced, unresectable, or metastatic GIST who have previously received imatinib mesylate and sunitinib malate. In September 2021, Bayer presented study results indicating close proximity to the prespecified activity threshold, possibly influenced by a low recruitment rate. The notable frequency of undetected mutant GIST by Sanger sequencing underscores the importance of next-generation sequencing (NGS) in presumed KIT/PDGFR wild-type GIST.

 

Gastrointestinal Stromal Tumor Emerging Therapies

 

  • Crenolanib: Arog Pharmaceuticals

Crenolanib, an investigational small molecule drug, is currently undergoing Phase III clinical trials to assess its safety and efficacy in treating acute myeloid leukemia (AML) and gastrointestinal stromal tumor (GIST). Acting as a potent inhibitor of both wild-type and mutant forms of FLT3 (FMS-like Tyrosine Kinase 3) and PDGFRα/β (Platelet-derived Growth Factor Receptor), Crenolanib holds promise as a potential additional treatment option for patients with advanced or metastatic GIST harboring a D842V mutation in the PDGFRA gene, offering hope for improved outcomes in this specific subgroup.

 

  • Bezuclastinib (CGT9486/PLX9486): Cogent Biosciences, Inc. / Plexxikon Inc.

Bezuclastinib (CGT9486) is a highly selective Type I inhibitor of KIT receptor tyrosine kinase, specifically targeting oncogenic KIT with mutations in the activation loop encoded by exons 17 and 18, including the pivotal KIT D816V mutation found in the majority of patients with systemic mastocytosis. The combination of bezuclastinib with sunitinib, a Type-II inhibitor effective against KIT ATP-binding pocket mutations, demonstrated prolonged progression-free survival in extensively treated patients with gastrointestinal stromal tumor. Cogent Biosciences, Inc. holds worldwide rights to bezuclastinib, encompassing all facets of development, manufacturing, and commercialization activities related to this promising molecule.

 

Get In-Depth Knowledge on Gastrointestinal Stromal Tumor Market Trends and Forecasts with DelveInsight @ Gastrointestinal Stromal Tumor Treatment Market

 

Gastrointestinal Stromal Tumor Market Outlook

Knowledge about the underlying genetic alterations revealed possible targeted treatment with TKIs such as imatinib and sunitinib. Continuous research efforts helped to further elucidate molecular insights of this disease and allowed the development of new treatment options based on the underlying molecular signature. Currently, there are seven therapies approved for GIST that includes five TKIs, and two NTRK inhibitors such as GLEEVEC (Imatinib Mesylate), STIVARGA (Regorafenib), SUTENT (sunitinib malate), AYVAKIT (avapritinib), QINLOCK (Ripretinib), ROZLYTREK (Entrectinib), and VITRAKVI (Larotrectinib), approved in different lines. Along with these, there are certain therapies being used as off-label therapies in patients resistant to approved therapies.

 

Scope of the Gastrointestinal Stromal Tumor Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM
  • Gastrointestinal Stromal Tumor Companies: Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others
  • Gastrointestinal Stromal Tumor Therapies: TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others
  • Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
  • Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Gastrointestinal Stromal Tumor Unmet Needs, KOL’s views, Analyst’s views, Gastrointestinal Stromal Tumor Market Access and Reimbursement

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Gastrointestinal Stromal Tumor Market Report @ Gastrointestinal Stromal Tumor Market Drivers and Barriers

 

Table of Content

1 Key Insights

2 Report Introduction

3 Gastrointestinal Stromal Tumor Market Overview at a Glance

4 Gastrointestinal Stromal Tumor Market and Epidemiology Methodology

5 Executive Summary of Gastrointestinal Stromal Tumors

6 Key Events

7 Gastrointestinal Stromal Tumor: Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Drugs

11 Emerging Drugs

12 Gastrointestinal Stromal Tumor: Seven Major Market Analysis

13 Key Opinion Leaders’ Views

14 SWOT Analysis

15 Unmet Needs

16 Reimbursement and Market Access

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastrointestinal Stromal Tumor Therapeutics Market Size in the 7MM was ~USD 450 Million in 2023, is expected to grow by 2034, and estimated DelveInsight

Adult-onset Still Disease Market Expected to rise, 2034 | Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., expected to drive market

“Adult-onset Still Disease Market Report 2034”
The Adult-onset Still Disease market growth is driven by factors like increase in the prevalence of Adult-onset Still Disease, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Adult-onset Still Disease market report also offers comprehensive insights into the Adult-onset Still Disease market size, share, Adult-onset Still Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Adult-onset Still Disease market size growth forward.

Some of the key highlights from the Adult-onset Still Disease Market Insights Report:

  • Several key pharmaceutical companies, including Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., and others, are developing novel products to improve the Adult-onset Still Disease treatment outlook.

  • DelveInsight’s epidemiology model estimates that in the US, there were approximately 2,325 diagnosed prevalent cases of AOSD in 2023. This number is expected to increase during the forecast period (2024-2034), driven by greater awareness, improved screening, and advancements in genetic testing.

  • Among the EU4 countries and the UK, Germany had the highest number of diagnosed prevalent cases of AOSD, with about 691 cases in 2023. France followed with approximately 560 cases, and the UK had nearly 550 cases.

  • According to DelveInsight, in 2023, there were approximately 7,464 diagnosed cases of Adult-Onset Still’s Disease (AOSD) across the 7 Major Markets (7MM). The United States accounted for about 31% of these cases, while the EU4 and the UK collectively represented around 37%, and Japan accounted for nearly 32%.

  • The AOSD market is expected to grow steadily, with a projected compound annual growth rate (CAGR) of 5% from 2024 to 2034. This growth is driven by the introduction of new therapies, such as Tadekinig Alfa, along with increased awareness, improved diagnosis, and advancements in treatment options.

  • A key unmet need in AOSD treatment is the lack of personalized therapeutic strategies, as current treatments often show variable efficacy and adverse effects. This highlights the need for more tailored approaches.

  • FDA-approved drugs like Canakinumab (Novartis), Anakinra (Swedish Orphan Biopharma), and Tocilizumab (Roche) for AOSD indicate significant market potential, reflecting the growing recognition of AOSD as a distinct therapeutic target.

  • The total Adult-onset Still Disease market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.

  • As per DelveInsight analysis, the Adult-onset Still Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Adult-onset Still Disease Market Landscape

Adult-onset Still Disease Overview

Adult-Onset Still’s Disease (AOSD) is a rare systemic inflammatory condition with an unknown cause, leading to significant morbidity. It typically presents with a combination of symptoms such as high fever, a characteristic rash, prolonged joint pain, and systemic issues like sore throat, splenomegaly, hepatomegaly, and lymphadenopathy. While the exact causes are unclear, AOSD may be triggered by environmental factors or infections in individuals genetically predisposed to the condition. Risk factors include a history of autoimmune diseases and age, as AOSD primarily affects adults between their 20s and 40s. The complexity of its diagnosis and the variability of symptoms make treatment and management challenging, underscoring the need for increased awareness and further research.

Diagnosing AOSD requires a thorough clinical evaluation, including a detailed patient history and identification of characteristic symptoms. Since AOSD is mainly a diagnosis of exclusion, other inflammatory and autoimmune disorders must be ruled out. Diagnostic procedures typically involve blood tests showing specific changes, such as elevated white blood cell counts and anemia. The erythrocyte sedimentation rate (ESR) test is crucial for measuring systemic inflammation. Additional tests may include C-reactive protein (CRP) levels, liver function tests, and serological assessments for other autoimmune diseases. The diagnosis is made by combining clinical findings with laboratory results, highlighting the need for a systematic approach to accurately identify AOSD.

Do you know the treatment paradigms for different countries? Download our Adult-onset Still Disease Market Sample Report

Adult-onset Still Disease Epidemiology Segmentation

DelveInsight’s Adult-onset Still Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Adult-onset Still Disease historical patient pools and forecasted Adult-onset Still Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Adult-onset Still Disease Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

  • Adult-onset Still Disease Prevalence

  • Age-Specific Adult-onset Still Disease Prevalence

  • Gender-Specific Adult-onset Still Disease Prevalence

  • Diagnosed and Treatable Cases of Adult-onset Still Disease

Visit for more @ Adult-onset Still Disease Epidemiological Insights

Adult-onset Still Disease Market Outlook

Adult-Onset Still’s Disease (AOSD) is an autoinflammatory disorder driven by the innate immune system, presenting with symptoms such as fever, rash, arthritis, pharyngitis, and liver and spleen involvement. Due to its rarity and the absence of large-scale studies, diagnosing AOSD is challenging, and treatment often follows an empirical approach based on small retrospective case series.

First-line treatments for AOSD include NSAIDs and corticosteroids, but many patients fail to achieve remission with NSAIDs, prompting the use of disease-modifying antirheumatic drugs (DMARDs) and biologics when corticosteroids are ineffective. Biologic agents targeting inflammatory pathways, such as interleukin (IL) receptor antagonists and TNF inhibitors, have become key therapies. KINERET (anakinra), an IL-1 receptor antagonist, is commonly prescribed for refractory cases, while ILARIS (canakinumab) has also been approved for AOSD, marking a significant therapeutic advancement. In Japan, ACTEMRA (tocilizumab), an anti-IL-6 receptor monoclonal antibody, is approved for patients who do not respond to other treatments.

Emerging treatments for AOSD include Tadekinig alfa, a recombinant IL-18 Binding Protein developed by AB2 Bio, which showed promise in early Phase II trials. However, limited recent data on its efficacy prevents its inclusion in future forecasts. Overall, the treatment landscape for AOSD is evolving, with ongoing research aimed at improving therapeutic options for patients.

Adult-onset Still Disease Marketed Drugs

  • ILARIS (canakinumab): NOVARTIS

  • KINERET (anakinra): Swedish Orphan Biovitrum

  • ACTEMRA (tocilizumab): Genentech (ROCHE)

Adult-onset Still Disease Emerging Drugs

  • Tadekinig Alfa: AB2 Bio

Adult-onset Still Disease Key Companies

  • Cerecor

  • Roche

  • Swedish Orphan Biovitrum

  • Novartis

  • Swedish Orphan Biovitrum

  • AB2 Bio Ltd.

  • And others

For more information, visit Adult-onset Still Disease Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Adult-onset Still Disease Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Adult-onset Still Disease, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Adult-onset Still Disease epidemiology in the 7MM

  • Adult-onset Still Disease marketed and emerging therapies

  • Adult-onset Still Disease companies

  • Adult-onset Still Disease market drivers and barriers

Table of Contents:

1 Adult-onset Still Disease Market Key Comprehensive Insights

2 Adult-onset Still Disease Market Report Introduction

3 Competitive Intelligence Analysis for Adult-onset Still Disease

4 Adult-onset Still Disease Market Analysis Overview at a Glance

5 Executive Summary of Adult-onset Still Disease

6 Adult-onset Still Disease Epidemiology and Market Methodology

7 Adult-onset Still Disease Epidemiology and Patient Population

8 Adult-onset Still Disease Patient Journey

9 Adult-onset Still Disease Treatment Algorithm, Adult-onset Still Disease Current Treatment, and Medical Practices

10 Key Endpoints in Adult-onset Still Disease Clinical Trials

11 Adult-onset Still Disease Marketed Therapies

12 Adult-onset Still Disease Emerging Therapies

13 Adult-onset Still Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Adult-onset Still Disease

16 Adult-onset Still Disease Market Key Opinion Leaders Reviews

18 Adult-onset Still Disease Market Drivers

19 Adult-onset Still Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Adult-onset Still Disease Epidemiology 2034

DelveInsight’s “Adult-onset Still Disease – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Adult-onset Still Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Adult-onset Still Disease Pipeline 2024

“Adult-onset Still Disease Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Adult-onset Still Disease market. A detailed picture of the Adult-onset Still Disease pipeline landscape is provided, which includes the disease overview and Adult-onset Still Disease treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Adult-onset Still Disease Market Expected to rise, 2034 | Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum, AB2 Bio Ltd., expected to drive market

LIVALL Unveils the Game-Changing PikaBoost 2 at CES 2025: Revolutionizing Cycling Innovation

LIVALL, a pioneer in smart cycling technology who introduced the world’s first smart and safe cycling helmet, is set to debut its next-generation e-bike conversion kit, the PikaBoost 2, at CES 2025. Showcasing at LVCC, North Hall, Booth 11033, this innovation aims to revolutionize the cycling experience. Following the success of the first generation in 2022, LIVALL PikaBoost 2 has earned recognition as a CES Innovation Awards 2025 Honoree in the Sustainability & Energy/Power category, solidifying LIVALL’s commitment to efficiency, adaptability, and sustainability.

The PikaBoost 2 combines a sleek design with robust performance. Its all-in-one module integrates a motor with a peak power output of 500W, a swappable lithium-ion battery, advanced regenerative braking, and LIVALL’s patented AAR 2.0 technology for precise, adaptive pedal assistance. From steep inclines to wet terrains and flat roads, the PikaBoost 2 seamlessly adjusts to meet every cyclist’s needs.

The PikaBoost 2 offers four versatile riding modes to suit various cycling needs: Power Assist Mode for tackling challenging terrains, Eco Assist Mode for extended battery life, Cruise Mode for effortless, steady rides, and Workout Mode for fitness enthusiasts. Designed with safety in mind, it features an intelligent e-braking system, real-time fall detection, slip detection, and an integrated LED rear light, ensuring a secure and seamless cycling experience for every rider.

As a highlight of CES 2025, LIVALL will announce its strategic partnership with a leading global two-wheel vehicle brand. At CES, the two companies will jointly showcase their integrated product that redefines cycling through connectivity and cutting-edge technology, further advancing the vision of a connected two-wheel mobility ecosystem.

“LIVALL is committed to focusing exclusively on the two-wheel mobility sector,” said Bryan Truth, Founder and CEO of LIVALL. “Our mission is to continually innovate and introduce new products that prioritize user experience and leverage advanced technology to redefine the cycling journey.”

CES attendees will be among the first to experience the PikaBoost 2’s game-changing features, along with LIVALL’s renowned smart helmets. These products are designed to elevate the cycling experience, catering to cyclists of all types, from casual commuters to dedicated fitness enthusiasts. The PikaBoost 2 reflects LIVALL’s vision of creating a smarter, safer, and more sustainable future for cyclists worldwide.

Join LIVALL at CES 2025 to experience the future of e-bike innovation. The PikaBoost 2 exemplifies how technology can transform traditional bicycles into efficient, eco-friendly, and versatile modes of transportation, stay tuned for more updates and exclusive insights as we gear up for this exciting unveiling.

Media Contact
Company Name: LIVALL
Contact Person: Alice LI
Email: Send Email
Country: United States
Website: https://livall.com/

Java for Beginners: ‘Build Your Dream Tech Career with Engaging Lessons and Projects’ Swift Learning Publication

The Book which has become one of the most talked about Books in its field is now available on Amazon in eBook and Paperback!

Java for Beginners is now the #1 Amazon Best Seller in the Java Computer Programming and Beginner’s Guides to Java Programming categories, rapidly becoming the essential resource for aspiring programmers. Perfect for those starting from the ground up or seeking to enhance their skills, this book provides a structured, easy-to-follow path for learning Java.

Discover how to:

  • Transition from novice to confident Java programmer
  • Learn with a blend of theory and practical exercises to ease you into Java programming
  • Future-proof your career with in-demand Java skills

Whether you’ve had challenges with programming before or are starting fresh, this guide is your ticket to a fulfilling tech career. Empower yourself to turn curiosity into expertise and dreams into reality.

The book begins with the basics, breaking down Java’s syntax and core concepts into easy-to-understand lessons. It then gradually moves to more advanced topics, such as object-oriented programming (OOP), arrays, collections, exception handling, and file management. With a blend of theory and hands-on exercises, readers can immediately apply what they learn to real-world coding challenges.

This book stands out with its practical approach, as each chapter presents clear examples and exercises. An additional bonus chapter explores the use of AI, particularly ChatGPT, in programming, aiding readers in understanding how modern tools can elevate their coding skills.

The book is ideal for those seeking to kickstart a career in software development, offering the foundational knowledge needed to progress in the tech industry. By the end of this book, you’ll have the confidence and skills to tackle Java programming and begin building your own projects, all while preparing for future success in tech.

“I’ve always dreamed of being a software engineer but didn’t know where to begin without formal schooling. This book was exactly what I needed. Java for Beginners starts with the basics and progresses in a way that’s easy to follow. The projects and exercises made me feel like I was learning something tangible and not just theory. It’s empowering to know I can work toward a career in software engineering on my own. Highly recommend this book to anyone starting from scratch!” – Valentin Bergstrom, KDP Customer

“Learning Java seemed like a daunting task until I came across Java for Beginners. This book is super beginner-friendly, with a logical flow and clear explanations. I loved the focus on real-world applications and how it starts from the absolute basics before moving to more advanced concepts. The hands-on exercises were a huge plus! If you’ve ever thought about coding but didn’t know where to start, this book will hold your hand every step of the way.” – Angel Doyle, KDP Customer

“Java for Beginners provides a strong foundation for understanding the basics of Java programming. The book introduces core concepts clearly and methodically, making it an excellent starting point for newcomers. It effectively equips readers with the knowledge and practical skills to begin coding in Java, offering well-structured venues for hands-on practice. The explanations are particularly commendable, with clear patterns and step-by-step examples that simplify complex topics. Each chapter includes exercises and sample answers, enabling readers to reinforce their learning and measure their progress. By following the book’s step-by-step approach diligently, readers are likely to achieve significant results in mastering Java fundamentals. Overall, this book is a valuable resource for anyone beginning their journey in Java programming.” – Steve Whang, KDP Customer

Java for Beginners: Build Your Dream Tech Career with Engaging Lessons and Projects is available on Amazon in ebook and paperback: Java for Beginners: Build Your Dream Tech Career with Engaging Lessons and Projects, Publication, Swift Learning, eBook – Amazon.com

Don’t wait to start your tech journey. Buy now to begin crafting your future in tech today!

For media inquiries, please contact:Dr. Anne Jae Brown

Swift Learning Publication

dba.dr.anne@gmail.com

Media Contact
Company Name: Swift Learning Publication
Contact Person: Dr. Anne Jae Brown
Email: Send Email
Country: United States
Website: https://www.amazon.com/dp/B0DFV594TD

Comprehensive Company Financial Reports and Profiles Revolutionize B2B Insights Across 185 Countries via Financh

“In today’s dynamic market landscape, accurate and timely data is not just an advantage but a necessity. At Financh, our mission is to empower businesses with the tools they need to make informed decisions, optimize strategies, and achieve sustainable growth,” said MD Sadique Akhter, CEO and President of Financh”

Financh, a global leader in private company intelligence, has set a new standard for B2B insights by delivering comprehensive company financial reports and detailed company profiles and analysis across 185 countries. With an extensive database of over 400 million private companies and a suite of advanced market intelligence tools, Financh is empowering businesses to make data-driven decisions and optimize strategies.

Transforming Business Decision-Making

Financh’s platform provides exhaustive company financial reports and analysis, offering detailed metrics such as income statements, balance sheets, cash flow statements, and financial ratios. These insights facilitate competitor analysis, company performance tracking, and competitive benchmarking, making it an indispensable tool for professionals across industries.

With a database spanning 185 countries and 250 industries, Financh enables businesses to navigate global markets with precision. The platform delivers key industry insights and equips professionals with tools to evaluate market trends, identify risks, and seize opportunities.

A Game-Changer for Investors

For venture capitalists, private equity firms, and investors, Financh provides unparalleled insights into funding activity reports, funding and investment data, and venture capital trends. Its tools enable the evaluation of private company data, funding rounds, and M&A (Mergers and Acquisitions) activity, giving users a competitive edge in identifying opportunities and mitigating risks.

“Our goal is to simplify complex data and present it in a way that empowers our clients to make proactive decisions,” added Sadique. “Whether it’s tracking business scores, understanding supply chain insights, or staying updated on industry trends, Financh provides a one-stop solution for global market intelligence.”

Investors also benefit from Financh’s detailed analysis of funding rounds, private company valuations, and M&A activity, enabling them to build robust strategies and evaluate opportunities in a competitive environment.

Comprehensive Insights for M&A and Compliance

Financh is a go-to resource for M&A insights, offering details on pre- and post-money valuations, deal-sourcing platforms, and transaction analysis. Businesses also benefit from corporate compliance checks, ensuring adherence to regulatory frameworks and reducing risk.

M&A professionals rely on Financh’s data to track the shifting deal landscape, evaluate merger arbitrage models, and identify strategic opportunities. The platform’s market intelligence tools provide real-time updates on global M&A activity across sectors and regions.

Market Intelligence Tools for Strategic Growth

Equipped with advanced market intelligence tools, Financh delivers in-depth industry insights and supply chain analysis, enabling businesses to identify emerging trends and evaluate competitive positioning. The platform’s competitive benchmarking and SWOT analysis tools offer a deeper understanding of market dynamics and business opportunities.

Financh’s proprietary deal forecasting and financial analytics tools help professionals anticipate trends, streamline decision-making, and optimize outcomes. Whether analyzing competitor profiles or assessing market risks, users can leverage Financh’s comprehensive resources to stay ahead.

Global Coverage and Cutting-edge Technology

With coverage spanning 185 countries and 250 industries, Financh provides a global perspective on market trends. Its innovative technology, including AI-driven financial analytics and advanced search tools, accelerates processes such as financial scoring, trend scoring, and deal forecasting, ensuring users stay ahead in a rapidly changing landscape.

The platform’s robust database includes startup directories, investor profiles, and detailed funding activity reports, catering to businesses and investors seeking actionable insights. Supply chain insights further empower users to identify vulnerabilities, enhance operational efficiency, and mitigate risks.

Tailored Solutions for Diverse Needs

From startup directories and investor profiles to funding activity reports and market intelligence tools, Financh offers solutions designed to meet the unique needs of corporate strategists, investors, and financial analysts. Supply chain insights further help businesses mitigate risks and enhance operational efficiency.

Financh’s ability to deliver tailored solutions makes it a trusted partner for professionals in sectors such as finance, technology, healthcare, and manufacturing. The platform’s tools are designed to address the diverse challenges of a globalized economy.

A Commitment to Excellence

Financh’s dedication to delivering accurate, timely, and comprehensive data has positioned it as a leader in private company intelligence. “The future of business lies in data-driven decisions,” Sadique emphasized. “At Financh, we are committed to providing our clients with the insights they need to thrive in an increasingly competitive global market.”

By integrating cutting-edge technology with a human-centric approach, Financh ensures its clients have access to actionable insights, empowering them to achieve sustainable growth and long-term success.

About Financh

Financh specializes in providing detailed company profiles, financial data, and market trends, empowering professionals to make informed decisions. With a database of over 400 million private companies and insights into funding rounds, M&A activity, and corporate strategies, Financh is transforming how businesses approach B2B insights.

For more information, visit https://financh.org.

Media Contact
Company Name: Financh
Contact Person: Press Team
Email: Send Email
Address:447 Broadway, 1137, 2nd Floor
State: New York
Country: United States
Website: https://financh.org/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Comprehensive Company Financial Reports and Profiles Revolutionize B2B Insights Across 185 Countries via Financh

Global Kinase Inhibitor in Autoimmune Diseases Market Size is anticipated to witness growth at a considerable CAGR by 2032, estimates DelveInsight

DelveInsight’s “Kinase Inhibitor in Autoimmune Diseases Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Kinase Inhibitor in Autoimmune Diseases, historical and forecasted epidemiology as well as the Kinase Inhibitor in Autoimmune Diseases market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

Discover Key Insights into the Global Kinase Inhibitor in Autoimmune Diseases Market with DelveInsight’s In-Depth Report @ Global Kinase Inhibitor in Autoimmune Diseases Market Size

 

Key Takeaways from the Kinase Inhibitor in Autoimmune Diseases Market Research Report

• The increase in Kinase Inhibitor in Autoimmune Diseases Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.

• As per DelveInsight analysis, the Kinase Inhibitor in Autoimmune Diseases Market is anticipated to witness growth at a considerable CAGR.

• The leading Kinase Inhibitor in Autoimmune Diseases Companies such as Pfizer, Eli Lily, Incyte Corporation, AbbVie, Gilead Sciences, Astellas Pharma, Japan Tobacco, Torii Pharmaceutical, Reistone Biopharma, Bristol Myers Squibb, Galapagos NV, Aclaris Therapeutics, Tahio Pharma, Oncostellae, Novartis Pharmaceuticals, Theravance Biopharma and Janssen (Johnson & Johnson), and many others.

• Promising Kinase Inhibitor in Autoimmune Diseases Pipeline Therapies such as Baricitinib, KPL-404, GSK3196165, SAR442168, and others.

 

Stay ahead in the Global Kinase Inhibitor in Autoimmune Diseases Therapeutics Market with DelveInsight’s Strategic Report @ Global Kinase Inhibitor in Autoimmune Diseases Market Outlook

 

Kinase Inhibitor in Autoimmune Diseases Epidemiology Segmentation in the 7MM

The epidemiology section of Kinase Inhibitor in Autoimmune Diseases offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

 

Download the report to understand which factors are driving Global Kinase Inhibitor in Autoimmune Diseases epidemiology trends @ Global Kinase Inhibitor in Autoimmune Diseases Prevalence

 

Kinase Inhibitor in Autoimmune Diseases Drugs Market

The Kinase Inhibitor in Autoimmune Diseases Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Kinase Inhibitor in Autoimmune Diseases signaling in Kinase Inhibitor in Autoimmune Diseases are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Kinase Inhibitor in Autoimmune Diseases Treatment Market Landscape

The Kinase Inhibitor in Autoimmune Diseases treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Kinase Inhibitor in Autoimmune Diseases has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

Kinase Inhibitor in Autoimmune Diseases Market Outlook

The report’s outlook on the Kinase Inhibitor in Autoimmune Diseases market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Kinase Inhibitor in Autoimmune Diseases therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Kinase Inhibitor in Autoimmune Diseases drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Kinase Inhibitor in Autoimmune Diseases market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Get In-Depth Knowledge on Global Kinase Inhibitor in Autoimmune Diseases Market Trends and Forecasts with DelveInsight @ Global Kinase Inhibitor in Autoimmune Diseases Treatment Market

 

Kinase Inhibitor in Autoimmune Diseases Drugs Uptake

The drug chapter of the Kinase Inhibitor in Autoimmune Diseases report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Kinase Inhibitor in Autoimmune Diseases.

 

Kinase Inhibitor in Autoimmune Diseases Companies

Several Kinase Inhibitor in Autoimmune Diseases Companies working in the market include Pfizer, Eli Lily, Incyte Corporation, AbbVie, Gilead Sciences, Astellas Pharma, Japan Tobacco, Torii Pharmaceutical, Reistone Biopharma, Bristol Myers Squibb, Galapagos NV, Aclaris Therapeutics, Tahio Pharma, Oncostellae, Novartis Pharmaceuticals, Theravance Biopharma and Janssen (Johnson & Johnson), and many others

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Global Kinase Inhibitor in Autoimmune Diseases Market Report @ Global Kinase Inhibitor in Autoimmune Diseases Market Drivers and Barriers

 

Scope of the Kinase Inhibitor in Autoimmune Diseases Market Research Report

  • Coverage- 7MM
  • Kinase Inhibitor in Autoimmune Diseases Companies- Pfizer, Eli Lily, Incyte Corporation, AbbVie, Gilead Sciences, Astellas Pharma, Japan Tobacco, Torii Pharmaceutical, Reistone Biopharma, Bristol Myers Squibb, Galapagos NV, Aclaris Therapeutics, Tahio Pharma, Oncostellae, Novartis Pharmaceuticals, Theravance Biopharma and Janssen (Johnson & Johnson), and many others
  • Kinase Inhibitor in Autoimmune Diseases Pipeline Therapies- Baricitinib, KPL-404, GSK3196165, SAR442168, and others.
  • Kinase Inhibitor in Autoimmune Diseases Market Dynamics: Kinase Inhibitor in Autoimmune Diseases Market Drivers and Barriers
  • Kinase Inhibitor in Autoimmune Diseases Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Table of Content

1. Key Insights

2. Executive Summary of Global Kinase Inhibitor in Autoimmune Diseases

3. Competitive Intelligence Analysis for Global Kinase Inhibitor in Autoimmune Diseases

4. Global Kinase Inhibitor in Autoimmune Diseases: Market Overview at a Glance

5. Global Kinase Inhibitor in Autoimmune Diseases: Disease Background and Overview

6. Patient Journey

7. Global Kinase Inhibitor in Autoimmune Diseases Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Global Kinase Inhibitor in Autoimmune Diseases Unmet Needs

10. Key Endpoints of Global Kinase Inhibitor in Autoimmune Diseases Treatment

11. Global Kinase Inhibitor in Autoimmune Diseases Marketed Products

12. Global Kinase Inhibitor in Autoimmune Diseases Emerging Therapies

13. Global Kinase Inhibitor in Autoimmune Diseases: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Global Kinase Inhibitor in Autoimmune Diseases

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Global Kinase Inhibitor in Autoimmune Diseases Market Size is anticipated to witness growth at a considerable CAGR by 2032, estimates DelveInsight

Glioblastoma Multiforme Treatment Market Size in the 7MM was ~USD 835 Million in 2023, is expected to grow by 2034, and estimates DelveInsight

DelveInsight’s “Glioblastoma Multiforme Market Insight, Epidemiology, and Market Forecast–2034” report delivers an in-depth understanding of GBM, historical and forecasted epidemiology as well as the GBM market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Discover Key Insights into the Glioblastoma Multiforme Market with DelveInsight’s In-Depth Report @ Glioblastoma Multiforme Market Size

 

Key Takeaways from the Glioblastoma Multiforme Market Report

  • Among the 7MM, the US accounted for approximately 41%, EU4 and the UK for 51%, and Japan for 8% of the total incident cases of GBM in 2023.
  • In the EU4 and the UK, in 2023, the maximum number of incident cases according to the histological classification was for glioblastoma with approximately 17,550 cases while the lowest incident cases were of giant cell glioblastoma type with approximately 150 cases, which are expected to increase by 2034.
  • In Japan, in 2023, the highest number of cases in the targeted therapy pool was for first-line treatments, with 2,690 cases, followed by second-line and above treatments with 1,365 cases.
  • As per the DelveInsight estimates, it has been found that the primary site of GBM included maximum cases at the parietal site, while the minimum number of cases were found in unknown and other sites. This trend is evident across all the 7MM countries for the study period.
  • The leading Glioblastoma Multiforme Companies such as Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharmaceuticals Bayer, MedImmune, DNAtrix, Chimerix, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, Treovir, Istari Oncology, and others.
  • Promising Glioblastoma Multiforme Pipeline Therapies such as Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.

 

Stay ahead in the Glioblastoma Multiforme Therapeutics Market with DelveInsight’s Strategic Report @ Glioblastoma Multiforme Market Outlook

 

Glioblastoma Multiforme Epidemiology Segmentation in the 7MM

  • Total Glioblastoma Multiforme Incident Population
  • Glioblastoma Multiforme Gender-specific Incidence Cases
  • Glioblastoma Multiforme Type-specific Incidence Cases
  • Glioblastoma Multiforme Incident Cases based on Primary Site
  • Glioblastoma Multiforme Age-specific Incidence Cases
  • Incident Cases Based on Histologic Classification of Glioblastoma Multiforme Tumor
  • Unmethylation of the MGMT Gene Promoter Cases,
  • BRAF V600E Mutation Cases
  • Line-wise Treated Pool

 

Download the report to understand which factors are driving Glioblastoma Multiforme epidemiology trends @ Glioblastoma Multiforme Prevalence

 

Glioblastoma Multiforme Marketed Drugs

 

  • AVASTIN (bevacizumab): Roche (Genentech)

AVASTIN is a recombinant humanized monoclonal IgG1 antibody, which acts as an angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). It binds to the VEGF with its receptors VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps reduce VEGF activity and regress the vascularization of tumors, normalizing the tumor vasculature and inhibiting the formation of new tumor vasculature, thereby preventing tumor growth. VEGF is a chemical signal that stimulates angiogenesis in various diseases, especially cancer.

 

  • TEMODAR/TEMODAL (temozolomide): Merck

The active pharmaceutical ingredient in TEMODAR/TEMODAL is an imidazotetrazine derivative of the alkylating agent dacarbazine. It is used for treating several brain cancer forms, e.g., as a second-line treatment for astrocytoma and a first-line treatment for GBM. The therapeutic benefit of TEMODAR is its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. TEMODAR targets tumoral tissues selectively; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity; and it is eliminated rapidly.

 

Glioblastoma Multiforme Emerging Drugs

 

  • DCVax-L: Northwest Biotherapeutics and Advent BioServices

DCVax-L is a fully personalized immune therapy made from a patient’s immune cells (dendritic cells) and antigens (biomarkers) from a sample of the patient’s tumor. DCVax-L is expected to be used for any solid tumor cancers in situations where the patient has their tumor surgically removed as part of standard care. DCVax -L is administered to the patient through a simple intradermal injection in the upper arm, similar to a flu shot. The dendritic cells then convey the tumor biomarker information to the rest of the immune system agents (T cells, B cells, and others) as “marching orders,” and the immune system agents fan out through the body, searching for anything with these biomarkers and attacking it.

 

  • TVI-Brain-1: TVAX Biomedical

TVI-Brain-1 is a patented vaccine-enhanced adoptive T-cell therapy (VACT) of TVAX Biomedical containing attenuated autologous cancer cells and activated autologous blood-derived T cells, developed through TVAX’s immunotherapeutic cancer treatment platform. TVAX Immunotherapy is a proprietary method for treating cancer using many activated, genetically unique cancer-specific killer T cells. This vaccination generates an immune response in the patient, producing many cancer-specific T cells. The activated killer T cells trigger the body’s immune system to destroy cancer cells, including cancer stem cells.

 

Get In-Depth Knowledge on Glioblastoma Multiforme Market Trends and Forecasts with DelveInsight @ Glioblastoma Multiforme Treatment Market

 

Glioblastoma Multiforme Market Outlook

Glioblastoma is a malignant brain tumor that develops from a specific type of brain cell called an astrocyte. These cells nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Unfortunately, there is no cure for glioblastoma. Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery, followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.

 

Scope of the Glioblastoma Multiforme Market Report

  • Coverage- 7MM
  • Glioblastoma Multiforme Companies- Genentech, Merck, Daiichi Sankyo, VBL Therapeutics, Diffusion Pharmaceuticals Bayer, MedImmune, DNAtrix, Chimerix, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, Treovir, Istari Oncology, and others.
  • Glioblastoma Multiforme Pipeline Therapies- Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.
  • Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme Market Drivers and Barriers

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Glioblastoma Multiforme Market Report @ Glioblastoma Multiforme Market Drivers and Barriers

 

Table of Content

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. GBM Market Overview at a Glance

7. Disease Background and Overview: GBM

8. Treatment and Management

9. Epidemiology and Patient Population

10. Patient Journey

11. Key Endpoints

12. Marketed Drugs

13. Emerging Drugs

14. GBM: Seven Major Market Analysis

15. Unmet Needs

16. SWOT Analysis

17. KOL Views

18. Market Access and Reimbursement

18.4. Market Access and Reimbursement of GBM

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Multiforme Treatment Market Size in the 7MM was ~USD 835 Million in 2023, is expected to grow by 2034, and estimates DelveInsight